First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
Varegacestat’s pivotal study reads out imminently.
The pivotal Harmoni-GI3 study has started enrolling patients.
The group will take HRS-4642 into a Chinese phase 3 in first-line pancreatic cancer.
Readout of the Preserve-003 trial in post-PD-(L)1 NSCLC is due in December.
ASH and SABCS approach.
The project has priority review, but deaths could raise eyebrows.